Kissei Pharmaceutical Co., Ltd.

Yu Kuramochi

Hideomi Takahashi

Takuro Dan

Takashi Miyagi

Masayuki Isaji

Kazuo Shimizu

Norihiko Kikuchi

Masahiro Hiratochi

Kazuya Tatani

Yoshinori Nonaka

An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Usage and dosage of therapeutic agents for endometriosis

The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; Rand Rare H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; Ris H, a halogen atom, optionally substituted alkyl group or the like; Rand Rare H, a halogen atom, OH or the like; and Rand Rare H or OH: Ris F or OH. 

Benzimidazole derivatives and medical uses thereof

Growing community of inventors

Tokyo, Japan

Yu Kuramochi